公开(公告)号：US20240109972A1

公开(公告)日：2024-04-04

申请号：US18038818

申请日：2021-12-07

Applicant: Genmab A/S ,  BioNTech SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Ulf FORSSMANN ,  Maria JURE-KUNKEL ,  Manish GUPTA ,  Tahamtan AHMADI ,  Kathy AMIRI ,  Gaurav BAJAJ

IPC: C07K16/28 ,  A61K31/337 ,  A61K45/06 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61K31/337 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2827 ,  A61K2039/505

Abstract: The present invention provides combination therapy to reduce or prevent progression of a tumor or treating cancer in a subject. The combination therapy comprises administration of a binding agent that binds to human CD137 and to human PD-L1; and a taxane chemotherapeutic agent.

公开(公告)号：US20230227570A1

公开(公告)日：2023-07-20

申请号：US17923317

申请日：2021-05-07

Applicant: GENMAB A/S

Inventor： Tahamtan AHMADI ,  Manish GUPTA ,  Tommy R. LI ,  Roberto OLIVERI ,  Dena DEMARCO ,  Ida HIEMSTRA ,  Christopher CHIU ,  Brian ELLIOTT ,  Ada AZARYAN

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2887 ,  C07K16/2809 ,  A61P35/00 ,  C07K2317/31 ,  A61K39/00

Abstract: The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).

公开(公告)号：US20210371538A1

公开(公告)日：2021-12-02

申请号：US17314946

申请日：2021-05-07

Applicant: GENMAB A/S

Inventor： Tahamtan AHMADI ,  Manish GUPTA ,  Tommy LI ,  Roberto OLIVERI ,  Dena DEMARCO ,  Ida HIEMSTRA ,  Christopher CHIU ,  Brian ELLIOTT ,  Ada AZARYAN

IPC: C07K16/28 ,  A61K31/573 ,  A61K45/06 ,  A61K39/395 ,  A61P35/00

Abstract: The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).

公开(公告)号：US20230087164A1

公开(公告)日：2023-03-23

申请号：US17795318

申请日：2021-02-04

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Isil ALTINTAS ,  Ulf FORSSMANN ,  Kate SASSER ,  Maria JURE-KUNKEL ,  Manish GUPTA

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer. The method comprises administering to a subject, a binding agent comprising a first binding region binding to human CD137 and a second binding region binding to human PD-L1. The amount of binding agent administered in each treatment cycle is preferably about 0.3-5 mg/kg body weight or about 25-400 mg in total.